It keeps pushing against that $6 dollar mark but hasn't yet gone through. It should definitely be well past that after its IIb data comes out (assuming positivity). We'll have to see if it can do so prior to it.
Well looks like i got the call on that one. Wish I'd bought more. Wasn't the toughest call though. We'll see if it peaks there. I tend to think it will stay around or just below 15 up until the adcom, trading rather narrowly from here on. Pdufa itself is still a few months away
Market cap isn't too high, but the whole entire biotech sector has been up hugely lately. It hasn't been just Cemp. The entire sector will probably come down again, at least some, before long here.
Same people said Mann's insulin pump would never work too I'm sure. Many people said we could never put a man on the moon, and some still even deny it today!
I don't know about the convention but I'm thinking the same: some news to come. They just cleaned up their balance sheet via the ContraVir spinoff, news of a buyout perhaps???
"The side effect profile of dalbavancin is mild with headache and pyuria being the most common." This was from a report over 10 years ago. Remember they've been studying this for a LONG time now. It's safe
Such reactions are rare though and generally mild. Maybe just some benadryl and an epi pen to go home with?
From an earnings perspective I too feel DRTX is very undervalued. As a RN I learned several years ago in nursing school about how our health care environment is changing and how managed care has lead to shorter hospital stays and growth in outpatient visits. Dalvance is very much in-line with this newer modality and the cost-cutting and savings that hospitals will reap from its use as opposed to having to admit patients for the purpose of putting them on continuous IV drips will eventually make it a monster product. This is beyond the fact that its efficacy has shown to be comparable to if not better than that of vancomycin to begin with.
It's a risky company I'd say but it's product has 500 million/year potential and its market cap is a mere 30 million, so tons of potential upside there. Does anyone know how its underlying finances are? I know inhibitex was bought out by bms for 2.5 billion a couple years ago prior to its failed hep c drug, not sure if any of that money is still at the disposal of ctrv today or how that works.
You only received 10 shares of ctrv for having 198 shares of sgyp?
Still waiting on receiving my shares from optionshouse.
Umm...no, you're the one who need to do better research there, novice.
1. Soli is active against MRSA, as the other poster just stated. In fact it binds to 3 recepter sites which in itself is unique. Most abxs only bind to one or two sites.
2. There have NOT been any other 4th generation macrolides that have succeeded, unless you count Ketek's failed drug as a success.
3. Again, I believe nano_machines summarized its non-inferiority pretty well in response to you. You obviously know nothing of what you write.
4. If you're shorting on margin, than you have my condolences. I have a few shirts lying around, let me know if you need on after you lose yours.
5. I could have gone further. For example Soli is going to be the first antibiotic approved for all age ranges, including pedis, in over 2 decades. It also has a BARDA contract for use of solithromycin against bioterror threat pathogens. It has shown no sign of hepatoxicity in its safety trials which is of utmost importance since this is what derailed Ketek. Oh, and of course, just the other day Cemra revealed the results of its most recent safety study which showed no evidence of QT prolongation/arrhythmia when supratherapeutic doses were administered. This makes alone makes it very unique as ALL macrolides to date have demonstrated this potential side effect.
Ketek's peak earnings estimate was originally estimated to be 1.5 billion a year IN THE US ALONE. By all accounts Soli is looking to be an even better abx. than Ketek was ever projected to be. Cempra's current market cap currently stands at 400 million something. You do the math after factoring in a reasonably projected market cap to earnings multiple of roughly 5X
If, by the way, you're shorting this stock on margin than you have my condolensces. I have some extra shirts lying around if you need one after you lose yours.